Our top pick for
Sesen Bio, Inc is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 25 staff and has a trailing 12-month revenue of around USD$11.2 million.
Since the stock market crash in March caused by coronavirus, Sesen Bio's share price has had significant positive movement.
Its last market close was USD$1.09, which is 21.91% up on its pre-crash value of USD$0.8512 and 194.59% up on the lowest point reached during the March crash when the shares fell as low as USD$0.37.
If you had bought USD$1,000 worth of Sesen Bio shares at the start of February 2020, those shares would have been worth USD$567.88 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,170.78.
|Latest market close||USD$1.09|
|52-week range||USD$0.37 - USD$1.54|
|50-day moving average||USD$1.1453|
|200-day moving average||USD$0.9769|
|Wall St. target price||USD$3.42|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.046|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||6.86%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$11.2 million|
|Gross profit TTM||USD$-24,663,000|
|Return on assets TTM||-17.5%|
|Return on equity TTM||0%|
|Market capitalisation||USD$148.7 million|
TTM: trailing 12 months
There are currently 1.8 million Sesen Bio shares held short by investors – that's known as Sesen Bio's "short interest". This figure is 2.1% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Sesen Bio shares can be evaluated.
Sesen Bio's "short interest ratio" (SIR) is the quantity of Sesen Bio shares currently shorted divided by the average quantity of Sesen Bio shares traded daily (recently around 2.2 million). Sesen Bio's SIR currently stands at 0.85. In other words for every 100,000 Sesen Bio shares traded daily on the market, roughly 850 shares are currently held short.
However Sesen Bio's short interest can also be evaluated against the total number of Sesen Bio shares, or, against the total number of tradable Sesen Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sesen Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sesen Bio shares in existence, roughly 10 shares are currently held short) or 0.0143% of the tradable shares (for every 100,000 tradable Sesen Bio shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sesen Bio.
Find out more about how you can short Sesen Bio stock.
We're not expecting Sesen Bio to pay a dividend over the next 12 months.
Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0.37 up to $1.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 1.2334. This would suggest that Sesen Bio's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.